Dergiler / Eurasian Journal of Medical Investigation / 2021 / Cilt: 5 - Sayı: 4

Intravenous Immunglobulins Are Not Effective in the Treatment of COVID-19

Sayfa
481–485
Yayın Tarihi
2022-10-12
DOI
—
🏛️Bu makalenin bibliyografik verileri ve tam metin bağlantısı DergiPark üzerinden sağlanmıştır.
DergiPark Kaydı ↗
✨

Yapay Zeka Hızlı Bakış & Çıkarımlar

AI Insight
⚡ TL;DR(1 Cümlede Hızlı Çıkarım)

However, IVIG therapy was not found to decrease mortality rate in severe COVID-19 patie

📌 3 Maddede Bu Makale

🎯
Amaç & Hipotez:Objectives: The COVID-19 disease caused a pandemic.
📊
Temel Bulgular & Veri:We report the effect of intravenous immunoglobulins in COVID-19 patients.
💡
Sonuç & Katkı:However, IVIG therapy was not found to decrease mortality rate in severe COVID-19 patie
🔬Tür:Araştırma Makalesi
📍Kapsam:Genişletilmiş Akademik Örneklem
⚙️Değişkenler:Alan Parametreleri

Abstract

Objectives: The COVID-19 disease caused a pandemic. Pneumonia and related hypoxia are known to be the most im- portant causes of mortality. An effective treatment is needed until extensive utilization of the vaccines. We report the effect of intravenous immunoglobulins in COVID-19 patients. Methods: As an observational case control study, demographic, clinical, laboratory, treatment, and outcome data of patients from Covid-19 ICU were obtained from records of the electronic medical archive of the hospital. Univariable and multivariable logistic regression methods were used to investigate the risk factors related to the length of hospital stay and in-hospital death. Results: All patients were treated with both corticosteroid and favipravir. Patients who received IVIG had a lesser amount of lymphocytes before treatment start. Eleven of the patients were died and 15 were alive. In alive patients, a significant increase in lymphocyte and decrease in ferritin levels were observed after high dose IVIG therapy. Conclusion: Increase in lymphocyte count and decrease in ferritin levels were observed in patients who survived after high dose IVIG therapy. COVID-19-related mortality toll is very high so an urgent effective treatment modality is still needed. However, IVIG therapy was not found to decrease mortality rate in severe COVID-19 patie

🔖

Bu Makaleye Atıf Yap

Kilic, I. (2022). Intravenous Immunglobulins Are Not Effective in the Treatment of COVID-19. Eurasian Journal of Medical Investigation, Cilt: 5 - Sayı: 4, 481–485. https://ajindex.com/articles/508563

📄 Tam Metin PDF Okuyucu

📄

PDF görüntüleyici hazırlanıyor...

Kaynakça (14)

  1. Chan JFW, Yuan S, Kok KH, To KKW, Chu H, Yang J. A familial cluster of pneumonia associated with the 2019 novel corona- virus indicating person-to-person transmission: a study of a family cluster. Lancet 2020;395:514–23
  2. Zumla A, Niederman MS, Zumla A. The explosive epidemic outbreak of novel coronavirus disease 2019 (COVID-19) and the persistent threat of respiratory tract infectious diseases to global health security. Curr Opin Pulm Med 2020;26:193–6
  3. Sharma A, Kilari S, Cai C, Simeon ML, Misra S. Increased fi- brotic signaling in a murine model for intra-arterial contrast- induced acute kidney injury. Am J Physiol Renal Physiol 2020;318:1210–9
  4. Schwab I, Nimmerjahn F. Intravenous immunoglobulin thera- py: how does IgG modulate the immune system? Nat Rev Im- munol 2013;13:176–89
  5. Galeotti C, Kaveri SV, Bayry J. IVIG‐mediated effector func - tions in autoimmune and inflammatory diseases. Int Immunol 2017;29:491–8
  6. Bonacina F, Baragetti A, Catapano AL, Norata GD. Long pen- traxin 3: experimental and clinical relevance in cardiovascular diseases. Mediators Inflamm 2013;2013:725102
  7. Ruan Q, Yang K, Wang W, Jiang L, Song J. Clinical predictors of mortality due to COVID-19 based on an analysis of data of 150 patients from Wuhan, China. Intensive Care Med 2020;46:846– 8
  8. Mehta P, McAuley DF, Brown M, Sanchez E, Tattersall RS, Man- son JJ; HLH Across Speciality Collaboration, UK. COVID-19: consider cytokine storm syndromes and immunosuppres- sion. Lancet 2020;395:1033–4
  9. Quinti I, Mitrevski M. Modulatory effects of antibody replace- ment therapy to innate and adaptive immune cells. Front Im- munol 2017;8:697
  10. De Ranieri D, Fenny NS. Intravenous immunoglobulin in the treatment of primary immunodeficiency diseases. Pediatr Ann 2017;46:e8–e12
  11. Buszko M, Park JH, Verthelyi D, Sen R, Young HA, Rosenberg AS. The dynamic changes in cytokine responses in COVID-19: a snapshot of the current state of knowledge. Nat Immunol 2020;21:1146–51
  12. Del Valle DM, Kim-Schulze S, Huang HH, Beckmann ND, Niren- berg S, Wang B, et al. An inflammatory cytokine signature pre- dicts COVID-19 severity and survival. Nat Med 2020;26:1636– 43
  13. Herth FJF, Sakoulas G, Haddad F. Use of intravenous immu- noglobulin for the treatment of COVID-19: retrospective case series. Respiration 2020;99:1145–53
  14. Gharebaghi N, Nejadrahim R, Mousavi SJ, Sadat-Ebrahimi SR, Hajizadeh R. The use of intravenous immunoglobulin gamma for the treatment of severe coronavir